ImCheck raises €20M, names CEO

Immuno-oncology company ImCheck Therapeutics S.A.S. (Marseille, France) raised €20 million ($21.8 million) in a series A round led by Boehringer Ingelheim Venture Fund, Kurma Partners and Idinvest Partners. Also participating were Gimv and LSP.

The company also named Pierre d’Epenoux CEO. He was chief strategy officer at Theravectys S.A. (Paris, France)...